Divis Laboratories Ltd
NSE: DIVISLAB BSE: 532488
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]
₹6,852
52W: ₹5636 — ₹7078
PE 70.8 · Book ₹578 · +1085% vs bookMarket Cap₹1,81,911 Cr
Stock P/E70.8Price to Earnings
ROCE20.6%Return on Capital
ROE15.6%Return on Equity
Div. Yield0.44%Face Value ₹2
Strengths
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 43.5%
Weaknesses
- −Stock is trading at 11.6 times its book value
- −The company has delivered a poor sales growth of 11.6% over past five years.
Shareholding Pattern
Promoters51.88%
FIIs20.29%
DIIs19.13%
Public8.61%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 51.89% | 51.89% | 51.89% | 51.89% | 51.88%▼0.0 | 51.88% | 51.88% | 51.88% |
| FIIs | 16.16% | 17.25%▲1.1 | 17.98%▲0.7 | 18.01%▲0.0 | 19.74%▲1.7 | 19.39%▼0.3 | 20.08%▲0.7 | 20.29%▲0.2 |
| DIIs | 21.66% | 20.98%▼0.7 | 20.44%▼0.5 | 20.63%▲0.2 | 18.96%▼1.7 | 19.68%▲0.7 | 19.18%▼0.5 | 19.13%▼0.1 |
| Public | 10.17% | 9.79%▼0.4 | 9.58%▼0.2 | 9.39%▼0.2 | 9.32%▼0.1 | 8.96%▼0.4 | 8.75%▼0.2 | 8.61%▼0.1 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,868 | 1,808 | 2,259 | 2,063 | 2,302 | 2,297 | 2,536 | 2,357 | 2,660 | 2,578 |
| Expenses | 1,394 | 1,317 | 1,542 | 1,442 | 1,573 | 1,550 | 1,655 | 1,614 | 1,765 | 1,671 |
| Operating Profit | 474 | 491 | 717 | 621 | 729 | 747 | 881 | 743 | 895 | 907 |
| OPM % | 25% | 27% | 32% | 30% | 32% | 33% | 35% | 32% | 34% | 35% |
| Net Profit | 342 | 358 | 531 | 430 | 518 | 594 | 667 | 557 | 696 | 598 |
| EPS ₹ | 12.88 | 13.49 | 20 | 16.2 | 19.51 | 22.38 | 25.13 | 20.98 | 26.22 | 22.53 |
AI Insights
Revenue Trend
TTM revenue at ₹10,131Cr, up 10.1% YoY. OPM at 34%.
Debt Position
Borrowings at ₹89Cr. Debt-to-equity ratio: 0.01x. Healthy balance sheet.
Capex Cycle
CWIP at ₹2,030Cr (36% of fixed assets). Significant capex underway — growth runway building.
Institutional Flow
DIIs: 19.13% (-2.02pp change). FIIs: 20.29% (+5.60pp change). Promoters hold 51.88%.
Margin & Efficiency
ROCE declining from 36% (Mar 2014) to 21% (Mar 2025). Working capital days: 193.
Valuation
PE 70.8x with 20.6% ROCE. Price is 1085% above book value of ₹578. Dividend yield: 0.44%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2d - Intimation of schedule of earnings conference call for the quarter and year ended March 31, 2026 to be held on May 23, 2026 at 14:30 …
- Announcement under Regulation 30 (LODR)-Newspaper Publication 2d - Copy of Newspaper Publication regarding loss of Share Certificate.
- Board Meeting Intimation for Considering And Approving Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31, 2026 And To Recommend Dividend, If Any, For The Financial Year 2025-26. 14 May - Board meeting on May 23, 2026 to approve FY26 results and consider dividend.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr - Certificate pursuant to Regulation 74(5) of the SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2026.
- Closure of Trading Window 31 Mar
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse